Inhaled Rev-56 for healthy volunteers and people with bronchiectasis
Part of Lungs & breathing clinical trials.
This trial tests an inhaled drug called Rev-56 in healthy adults and in adults with non-cystic fibrosis bronchiectasis who have a chronic lung infection with Pseudomonas aeruginosa. It aims to see if the drug is safe, well-tolerated, and helps reduce the bacteria in the lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old (for patients with bronchiectasis) or 18 to 55 (for healthy volunteers).
- If you have bronchiectasis, it must be confirmed by a CT scan and you must have had at least 2 positive sputum cultures for Pseudomonas aeruginosa in the past year.
- Your lung function (FEV1) must be at least 50% of predicted (for patients) or 80% (for healthy volunteers).
- You cannot have asthma, COPD, or cystic fibrosis if you are a patient with bronchiectasis.
- You should not have had more than 2 flare-ups needing IV antibiotics in the past year, and you should not have taken antibiotics (except macrolides) in the last 30 days.
- Healthy volunteers must have a normal physical exam and lab results, and not be a current smoker or have a history of substance abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests an inhaled medication for people with bronchiectasis, a lung condition causing chronic cough and mucus. It first checks safety in healthy volunteers, then studies how the drug works in people with bronchiectasis.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.